0001558370-23-011700.txt : 20230705 0001558370-23-011700.hdr.sgml : 20230705 20230705163738 ACCESSION NUMBER: 0001558370-23-011700 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230701 ITEM INFORMATION: Other Events FILED AS OF DATE: 20230705 DATE AS OF CHANGE: 20230705 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ampio Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001411906 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 260179592 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35182 FILM NUMBER: 231069817 BUSINESS ADDRESS: STREET 1: 9800 MOUNT PYRAMID COURT, SUITE 400 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: 720-437-6500 MAIL ADDRESS: STREET 1: 9800 MOUNT PYRAMID COURT, SUITE 400 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: Chay Enterprises, Inc. DATE OF NAME CHANGE: 20070910 8-K 1 ampe-20230701x8k.htm 8-K
0001411906false00014119062023-07-012023-07-01

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) 

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 1, 2023

AMPIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

​

​

​

​

Delaware

001-35182

26-0179592

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer Identification No.)

​

9800 Mount Pyramid Court, Suite 400

Englewood, Colorado 80112

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (720) 437-6500

​

373 Inverness Parkway, Suite 200

Englewood, Colorado 80112

(Former name, or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value

AMPE

NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

​

Item 8.01.

Other Events.

​

Effective July 1, 2023, Ampio Pharmaceuticals, Inc. changed the address of its principal executive offices to:

​

Ampio Pharmaceuticals, Inc.

9800 Mount Pyramid Court, Suite 400

Englewood, Colorado 80112

​

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

 

AMPIO PHARMACEUTICALS, INC.

 

 

 

 

 

Date:  July 5, 2023

By:

/s/ Michael A. Martino

 

 

 

Name: Michael A. Martino

 

 

 

Title: Chief Executive Officer

​

​

​

​

​

 EX-101.SCH 2 ampe-20230701.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ampe-20230701_lab.xml EX-101.LAB EX-101.PRE 4 ampe-20230701_pre.xml EX-101.PRE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Jul. 01, 2023
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Jul. 01, 2023
Entity File Number 001-35182
Entity Registrant Name AMPIO PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 26-0179592
Entity Address, Address Line One 9800 Mount Pyramid Court, Suite 400
Entity Address, City or Town Englewood
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80112
City Area Code 720
Local Phone Number 437-6500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol AMPE
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Central Index Key 0001411906
Amendment Flag false
XML 6 ampe-20230701x8k_htm.xml IDEA: XBRL DOCUMENT 0001411906 2023-07-01 2023-07-01 0001411906 false 8-K 2023-07-01 AMPIO PHARMACEUTICALS, INC. DE 001-35182 26-0179592 9800 Mount Pyramid Court, Suite 400 Englewood CO 80112 720 437-6500 false false false false Common Stock, $0.0001 par value AMPE NYSEAMER false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ampe-20230701x8k.htm ampe-20230701.xsd ampe-20230701_lab.xml ampe-20230701_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ampe-20230701x8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "ampe-20230701x8k.htm" ] }, "labelLink": { "local": [ "ampe-20230701_lab.xml" ] }, "presentationLink": { "local": [ "ampe-20230701_pre.xml" ] }, "schema": { "local": [ "ampe-20230701.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ampe", "nsuri": "http://www.ampiopharma.com/20230701", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ampe-20230701x8k.htm", "contextRef": "Duration_7_1_2023_To_7_1_2023_gUQ6tP7viU-qe1cLg9X0gg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ampe-20230701x8k.htm", "contextRef": "Duration_7_1_2023_To_7_1_2023_gUQ6tP7viU-qe1cLg9X0gg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "ampe_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.ampiopharma.com/20230701", "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.ampiopharma.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001558370-23-011700-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-011700-xbrl.zip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